Skip to main content

Table 1 Baseline characteristics of S-TPI cases and those in SITS-UK and VISTA with mRS of ≤ 2 pre treatment

From: Development of a decision analytic model to support decision making and risk communication about thrombolytic treatment

  S-TPI N = 2,131   SITS-UK, N = 2,401 VISTA untreated N = 4,630
Characteristic   Cases omitted from analyses (n = 227) Patients: surviving at 3-months (n = 1,996) Patients: not surviving to 3-months (n = 405)  
Age mean (SD) 65.9 (11.4) 67.8 (13.26) 66.7 (12.7) 73.3 (11.3) 70.5 (12.2)
Sex, % male 54.7 % 58.6 % 58.7 % 56.5 % 51.6 %
NIHSS score (median, IQR) 12 (8,17) 12 (7,18)b 12 (8,17) 19 (15,22) 13 (8,18)
Hypertension % 58.8 % 60.36 % 58.0 % 62.5 % 72.1 %a
Diabetes % 20.8 % 14.9 % 12.0 % 17.3 % 21.4 %
Prior stroke % 16.6 % 14.41 % 13.6 % 14.8 % 34.3 %a
Atrial fibrillation % 18.6 % 27.0 % 23.6 % 30.6 % 31.6 %
Onset time to treatment (OTT) minutes (median, IQR) 235 (155,290) 146 (109,175) 150 (120, 175) 150 (120, 178) -
OTT, % within 3–4.5 h 61.3 % 15.3 % 16.6 % 17.3 % -
Systolic blood pressure, mm Hg (mean, SD) 152.6 (20.3) 145.5 (21.8)a 146.9 (20.8) 147.9 (21.0) 156.8 (26.7)
Serum glucose mmol/l (median, IQR) 6.78 (5.83,8.58) 6.2 (5.6,7.8) 6.2 (5.4, 7.5) 6.9 (6.0, 8.4) 6.7 (5.8,8.5)
Signs of current infarction on pre-treatment scan % NA 23.9 % 24.3 % 34.8 % NA
Congestive heart failure % 12.1 % 4.5 % 4.6 % 6.9 % NA
  1. aignoring missing values, bNational Institutes of Health Stroke Scale
  2. S-TPI = Stroke-Thrombolytic Predictive Instrument
  3. SITS-UK = Safe Implementation of Treatments in Stroke UK